



veno-venous double lumen 
ECMO: complications and 
survival in infants with 
respiratory failure
ABSTRACT
Objective. To compare complications and survival between the two-site veno-venous versus the veno-venous double lumen 
extracorporeal membrane oxygenation (ECMO) in infants with respiratory failure. 
Methods. The Extracorporeal Life Support Organization (ELSO, Ann Arbor, Michigan) provided the registry database, collec-
ted between 1999-2009 for this research project. During this period, 9086 infants  7 kg birth weight (BW) were treated 
with ECMO. From these children, those who were older than 32 days and received veno-venous extracorporeal membrane 
oxygenation (VV ECMO), were extracted for analysis. From a total of 270 infants who met the inclusion criteria, 236 infants 
were treated with veno-venous double lumen (VVDL) ECMO and 34 infants received VV two-site ECMO. ELSO records were 
reviewed for the following information: demographic data, type of ventilation, ventilator days and settings during ECMO, 
complications during ECMO and survival.
Results. Eighty-seven percent (n=236) of infants were cannulated with VVDL and 13% (n=34) with VV two-site cannulation. 
Twenty-four hours after ECMO onset, ventilator settings were significantly higher in the VV two-site group. Median ECMO 
duration was significantly shorter in the VV two-site group (137(90/208) vs. 203(128/336) hours, p=0.01). Total complication 
rate and survival rates (71% in the VVDL group and 56% in the VV two-site group) were not significantly different. 
Conclusion. Both cannulation modes for ECMO are safe for use in infants with respiratory failure. The decision regarding 
which technique should be used for this group of patients depends mainly on best practice experience of the individual 
ECMO center and on the technical equipment routinely used by the center.
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Introduction
Extracorporeal membrane oxygenation 
(ECMO) provides temporary life support 
for children with severe respiratory or 
cardiac failure. Since 1990, more than 
29,000 children with respiratory failure 
have received ECMO. The overall survi-
val rate reported by the Extracorporeal 
Life Support Organization (ELSO) is 
75% in neonates and 56% in children. 
(1) Despite its technical complexity and 
the need for experienced staff (usu-
ally designated as the “ECMO-team”), 
ECMO support has clearly achieved an 
important role in pediatric critical care. 
Although many previous studies des-
cribe ECMO treatment in neonatal or 
pediatric respiratory failure, (2-10) the 
impact of different veno-venous ECMO 
methods has remained unconsidered. 
ELSO provides a data registry dating 
back to 1989. All ECMO centers, which 
are members of ELSO, report their 
ECMO cases, devices, complications 
and follow-up status to this registry in 
an anonymous form. For this purpose, 
each center uses standardized data 
capture forms for each patient. Since 
1990, more than 30,000 treatments 
were added to the database containing 
data from neonatal, pediatric and adult 
ECMO cases. Currently, data from 116 
US and 14 international centers are 
submitted to ELSO. Submission of 
cases to the ELSO registry is voluntary. 
A database of information relating to 10 
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years of international experience was 
provided by ELSO for this study. 
The objective of this study was to 
compare complications and survival 
between veno-venous two-site ECMO 
(VV ECMO) and veno-venous double 
lumen ECMO (VVDL ECMO) in infants 
with respiratory failure.
Methods
This study was designed as a retrospec-
tive chart review study. Until recently, 
most pediatric ECMO studies reported 
on neonates (body weight 2.5-3.5kg) 
and/or children (body weight > 10kg) 
but not specifically on infants (body 
weight 4-10 kg). The median weight of 
an infant of 6 months according to inter-
national percentile curves is 8 kg body 
weight for boys and 7,2 kg body weight 
for girls. (11) We therefore, set the cut-
off point for the inclusion criteria at < 
7kg body weight and age of > 32 days 
for infants which were included in this 
study. This study aims to fill, or at least 
narrow, this gap. From 1999 until 2009, 
the registry recorded 9,086 ECMO runs 
in infants with a body weight  7kg. 
Using the ’mode of bypass’ data field 
as a sorting tool, two groups of patients 
were identified among all infants older 
than 32 days: the VV two-site ECMO 
group and the VVDL ECMO group. Two 
hundred and seventy infants met the 
inclusion criteria of which 236 infants 
(87%) were treated with VVDL ECMO 
and 34 infants (13%) were treated with 
VV two-site ECMO. Children who had 
received other modes of ECMO were 
not included in this study. The decision 
to use VV ECMO was made at each 
centre according to their own ECMO 
criteria. Only data from the first ECMO 
run were analyzed. Anonymity of the 
data could be assured as data were 
related to patient identification (ID) 
numbers in the ELSO registry. Each 
institution approved data reported to 
ELSO through their local institutional 
review board. The Hospital Research 
Ethics Committee reviewed the study 
protocol. And the requirement for ethi-
cal approval was waived.
Data management
Data were reviewed for the following:
Demographic data
Primary diagnoses: determined accor-
ding to the International Classification 
of Diseases (ICD 9).
Pre-ECMO support: evidenced by the 
existence of support codes for vaso-
pressor/inotropic drugs, vasodilator 
drugs, cardiopulmonary bypass, high 
frequency ventilation/oscillation, nitric 
oxide, surfactant, narcotics, neuromus-
cular blockers, bicarbonate, dopamine, 
dobutamine, milrinone and steroids. 
ECMO course data: age in days, cannu-
lation mode (percutaneous/surgical), 
duration of ECMO in hours, cannula 
site repair, the year ECMO was perfor-
med, pre-ECMO duration of ventilation, 
ventilation type at ECMO beginning and 
after 24 hours on ECMO. 
Ventilation settings: fractional inspired 
oxygen (FiO2), respiratory rate, peak 
inspiratory pressure (PIP), positive 
end expiratory pressure (PEEP), mean 
airway pressure (MAP).
Complications
Mechanical: clots in the oxygenator, 
bladder, bridge, haemofilter, cannula 
problems, air in the circuit, oxygena-
tor failure, raceway/tubing rupture and 
pump/heat exchanger malfunction.
Neurologic: seizures, clinically deter-
mined/electroencephalography (EEG) 
determined central nervous system 
(CNS) infarction/hemorrhage by ultra 
sound (US) /computed tomography (CT) 
and brain death clinically determined.
Hemorrhagic: cannulation/surgical site 
bleeding, gastrointestinal hemorrha-
ge, hemolysis, hemoglobin >50mg/dL, 
disseminated intravascular coagulation 
(DIC).
Renal: creatinine 1.5-3.0 mg/dL > 3.0 
mg/dL, dialysis/hemofiltration/continu-
ous arterio-venous hemodialysis requ-
ired. 
Cardiovascular: inotropes on extracor-
poreal life support (ECLS), cardiopul-
monary resuscitation (CPR) required, 
cardiac arrhythmia, myocardial stun 
by echo, hypertension requiring vaso-
dilators, tamponade (blood/serous/
air), Persistent ductus arteriosus (PDA) 
(LR, RL, bidirectional, unknown).
Pulmonary: pneumothorax requiring 
treatment, pulmonary hemorrhage.
Infectious: culture-proven infection, 
white blood count (WBC) < 1.500
Metabolic: glucose <40g/dL>240g/
dL, ph < 7.20/> 7.60, hyperbilirubi-
nemia (direct > 2mg/dL, indirect > 
15mg/dl).
Outcome: discharge from ECLS center 
(either to home, or to another center), 
reasons for discontinuation (recovery 
or reasons for death).
Statistical analysis
Data were received in Excel (Microsoft 
Inc., Redmond, WA, US) format from 
the ELSO registry and then transferred 
for statistical analysis to an SPSS file 
(SPSS® version 15.0, Chicago IL, US). 
Data is presented as the median and 
interquartile range (IQR) (25th and 75th 
percentile) or as a percentage. For 
categorical data, Chi-square tests were 
used, and for continuous data, Mann-
Whitney U tests are used. Statistical 
significance was accepted at p < 0.05
Results
Demographic data 
Demographic data is shown in table 
1. There was no significant difference 
noted between genders. Infants in the 
VVDL group had a lower gestational 
age (30 vs. 39 weeks, p=0.01) but the 
age at the start of ECMO did not differ 
significantly. However, the birth wei-
ghts (1.8 vs. 3.7kg BW, p=0.014) and 
current weights (3.9 vs. 4.5, p=0.049) 
observed in the VVDL group were signi-
ficantly lower. 
The primary diagnoses were defined 
by ICD 9 codes (International Classi-
fication of Disease, 9th Revision) and 
classified into disease groups as listed 
in table 2.
The most common primary diagnosis 
was viral pneumonia: 44% in the VVDL 
group and 21% in the VV two-site group 
(e.g. respiratory syncytial virus, adeno-
virus and parainfluenza virus). 
Pre-ECMO data
Groups showed no difference in total 
amount of pre-ECMO support (96 vs. 
91%). Analyses of the pre-ECMO sup-
port stage in specific categories, howe-
ver, showed a significant difference when 
vasopressors / inotropic drugs were 
administered (64 vs. 82 %, p=0.03). 
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ECMO course data
There were no differences between gro-
ups in relation to the mode of cannula-
tion (percutaneous or surgical cannu-
lation 170/66 vs. 23/11) used or the in 
relation to the duration of ventilation 
observed before ECMO was started 
(102.5(44.5/191.7) vs. 59(22.2/172) 
hours). The duration of ECMO was 
significantly shorter in the VV two-site 
group (137(90/208) vs. 203(128/336) 
hours, p=0.01).
There was no significant difference 
noted between groups with regards to 
the ventilation mode used pre-ECMO. 
Twenty-four hours after the onset of 
ECMO, PIP and MAP were signifi-
cantly higher in the VV two-site group 
(22(20/27) vs. 26(20/31), p=0.0174 
and 12(10/14) vs. 14(10/18), p=0.049) 
than in the VVDL group, respectively.
Complications 
ECMO-treatment without complica-
tions was found in 14% of the VVDL 
group and in 21% of the VV two-site 
group. Eighty-six percent of the VVDL 
group and 79% of the VV two-site group 
experienced at least one complication 
during ECMO, with a median of 2 com-
plications per patient in both cohorts. 
The most frequent complications are 
classified and listed in table 3. The most 
frequent mechanical complication was 
defined as ’cannula problems’ (20% of 
all children). This occurred more frequ-
ently in the VVDL group than in the VV 
two-site group (21% vs. 12%). 
Outcome
ECMO survival rates were 82% in the 
VVDL group and 68% in the VV two-site 
group. Overall, 217 infants from 270 
study patients (80%) survived ECMO of 
which 71% in the VVDL group and 56% 
in the VV two-site group were dischar-
ged alive from the ICU. This difference 
was not statistically significant.
Discussion
In this chart review study of infants with 
respiratory failure, no difference in the 
total complication and overall survival 
rate was observed between the VV two-
site and the VVDL ECMO group. Among 
a number of potential complications 
associated with ECMO, intracranial 
hemorrhage or infarction, during bypa-
ss, is perhaps the most devastating. 
This analysis showed a neurological 
complication rate of approximately 0.5-
6% in both groups, with a marginally 
lower rate in the VV two-site group. The 
etiology of these neurological injuries is 
multifactorial: abrupt changes in local 
and systemic blood pressure, ische-
mia/reperfusion, anticoagulation and 
venous hypertension caused by distal 
internal vein ligation are reported to play 
a contributory role. (4)
The duration of pre-ECMO mechanical 
Table 1. Demographic data.
VVDL VV p Value
Gender (M / F; %) 57.2/ 41.5 41.2/ 58.8 n.s
Gestational Age (weeks) 30 (27/38) 39 (38/40) 0.01
Birth weight (kg body weight) 1.8 (0.9/2.9) 3.7 (2.9/3.9) 0.014
Age at ECMO start (days) 109 (64/156) 127 (65/176) 0.474
Weight at ECMO start 
(kg body weight)
3.9 (3/5) 4.5 (3.8/5.7) 0.049
Data are presented as the median and IQR (25th and 75th percentile) for parametric varia-
bles or as a percentage (%) for categorical variables. Statistical significance was accepted 
at p < 0.05. 
ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; M/F, male/female; 
n.s, not significant; VV veno-venous two site ECMO group; VVDL, veno-venous double lumen 
ECMO group.
Table 2. Primary diagnoses.
VVDL VV
Viral pneumonia 44 21
Bacterial pneumonia 3 6
Infection (e.g. acute bronchiolitis, 
pertussis)
13 18
Respiratory disease (e.g. tracheal 
stenosis, primary pulmonary 
hypertension)
14 21
Respiratory insufficiency, non-traumatic 9 6
ARDS 5 9
Congenital heart disease 4 6
Other 8 15
Data are presented as a percentage (%) for categorical variables. Statistical significance was 
accepted at p < 0.05.
ARDS, acute respiratory distress syndrome; VV, veno-venous two site ECMO group; VVDL, 
veno-venous double lumen ECMO group.
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ventilation did not differ significantly 
between groups. Swaniker et al. (5) 
reported that the only pre-ECMO vari-
able that correlated with survival was 
pH and they were surprised that the 
pre-ECMO period of mechanical ven-
tilation was not predictive of outcome, 
as shown previously for adults. (12,13) 
With regard to ECMO, they also obser-
ved that survival was strongly associ-
ated with the presence of renal failure 
and the need of inotropes.
In both study groups, some of the veno-
us cannulae were placed percutaneously 
(VVDL 72%, VV two-site 67%). This sim-
plifies access and avoids ligation of the 
veins. The VVDL cannulation technique 
is more feasible in neonates and small 
infants, where cannulation of the femoral 
vein is difficult, usually because of the 
risk of vascular compromise to the leg. 
Furthermore, it is quite difficult to place a 
venous cannula in a femoral vein, which 
is large enough to achieve adequate 
drainage or allow adequate return, in an 
infant with less than 7 kg body weight. 
Therefore, in children who cannot yet 
walk, VVDL bypass is often used as the 
preferred ECMO mode of VV-ECMO, 
otherwise VA-ECMO must be used. (14) 
The VVDL cannula can also eliminate 
other risks of VA ECMO, such as incre-
ased pulmonary vascular resistance, 
(15) compromised regional blood flow 
to vital organs, (16) decreased coronary 
artery oxygen transport, (17,18) impa-
ired cardiac performance (19,20) and 
altered cerebral perfusion or autoregula-
tion. (21,22) Nevertheless, the size of the 
double lumen cannula required for older 
children is considerable and therefore 
a different mode of VV ECMO may be 
more suitable. The use of cannulae with 
smaller diameters, as used in VV two-site 
ECMO, may be beneficial for the blood 
vessels in such cases. (23) Since, in this 
study, infants in the VVDL group had 
significantly lower birth weight and body 
weight when ECMO was initiated, this 
may explain why most ECMO centers 
preferred this technique of cannulation 
for their patients. This might also expla-
in, the unbalanced number of patients 
between study groups (VVDL n=236 vs. 
VV two-site n=34). 
To identify possible differences in the 
clinical status between groups and 
explain our findings, we looked at the 
primary diagnoses and total pre-ECMO 
support provided to each patient before 
starting ECMO. We found that primary 
diagnoses (table 2), ventilation time 
before ECMO and total pre-ECMO sup-
port (96% in VVDL versus 91% in the VV 
two-site) did not differ between groups. 
All these findings suggest that groups 
did not differ in their clinical status when 
ECMO support was initiated. Although 
analysis of all the single, specific criteria 
of pre-ECMO support showed a signifi-
cantly higher need of inotropic support 
and also significantly higher MAP and 
PIP values after 24 hours of ECMO in 
the VV two-site group (table 3), it cannot 
be concluded that these infants were 
more unwell or sicker than those in the 
VVDL group. This is supported by the 
results of Roberts et al. (3) who showed 
that the level of inotropic support provi-
ded to ECMO patients during an ECMO 
run did not provide a good tool for dis-
tinguishing between survivors and non-
survivors. Diagnosis was much more 
relevant for this purpose. 
Duration of ECMO was significantly 
shorter in the VV two-site group, but it is 
not possible to judge whether VV two-
site cannulation improves outcomes 
compared with VVDL techniques, since 
this finding may also be influenced by 
the lower survival in the VV two-site 
group (56% vs. 71%, p=0.071), leading 
to earlier discontinuation of ECMO at 
death. Pettignano et al. (2) reported a 
median ECMO duration of 218 hours 
in 68 VV patients, with a survival rate 
at discharge of 77%. In this analysis, 
ECMO duration in both groups was 
shorter and the overall survival at disc-
harge was 69%. 
Although many authors recommend VV 
cannulation for acute respiratory failure, 
VA cannulation remains more common. 
(24,25) Zahraa et al. compared VA ver-
sus VV modes in pediatric patients with 
respiratory failure. The VV mode yiel-
ded survival rates (60%) equal to VA 
ECMO (56%) in children. (26) A recently 
published study by Zabrocki et al. (27) 
demonstrated that among pediatric 
patients cannulated for respiratory fai-
lure, hospital survival rate was 70% for 
children supported by a VVDL-ECMO, 
66%for those supported by VV two-site 
ECMO , and a significantly lower 51% in 
children supported by VA ECMO.
The benefits of VV ECMO are manifold: 
avoidance of carotid artery ligation, 
preservation of coronary arteries and 
lung perfusion with oxygenated blood, 
and maintenance of normal cerebral 
blood flow velocities. (18, 23) The risk 
of complications is lower in VV ECMO. 
In particular, the consequences of cir-
cuit emboli are worse when VA ECMO 
is used. 
No prospective randomized studies 
have so far compared the benefit of 
ECMO in pediatric respiratory failure to 
conventional strategies. In a retrospecti-
ve multi-centre study reported by Green 
et al. outcomes with ECMO were 47% 
compared to 26% survival in the control 
group treated with conventional thera-
py. (28) ECMO will remain as a rescue 
therapy in most centers for patients in 
whom the likelihood of survival with the 
continuation of conventional therapy 
appears inaccessible. In that respect, 
the overall survival of patients in this 
study (69%, in both groups) appears 
encouraging. 
Brogan et al. recently completed a mul-
ti-center case review study in adults 
with severe respiratory failure treated 
with ECMO. (29) Most of their alluded 
primary design limitations are also sui-
table for this study in infants. They arise 
from its retrospective and uncontro-
lled nature, including the absence of 
standardized criteria for using ECMO. 
Important variables such as patient 
selection or indication for ECMO are 
neither included in the ELSO database 
nor standardized in the ELSO database 
forms, since these are rather center 
specific decisions. Data coding and 
data entry into the data capture forms 
are performed by each center and 
many fields remain empty at the time 
of data submission to the ELSO regi-
stry. Further, diagnoses are recorded 
using the ICD-9 coding system, which 
has well-described shortcomings. (30) 
These disadvantages are confounded 
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by the fact that the ELSO registry does 
not release information on ECMO cen-
ters, and therefore no conclusions can 
be made about the influence of center 
trends.
It is therefore advised that prospective 
clinical trials should be performed in 
infants to determine validated criteria 
for pediatric patient selection for VV 
ECMO. Investigations regarding diffe-
rent ECMO modes should be continu-
ed in infants and may further improve 
pediatric survival after ECMO in infants 
with severe respiratory failure.
Conclusions
The total complication rate was found to 
be similar in both groups. No difference 
was found in survival rates between the 
two groups. Neither of the two-cannu-
lation methods – veno-venous two-site 
or veno-venous double lumen ECMO 
Table 3. Complications during ECMO.
VVDL VV % of all patients
Mechanical
Cannula problems 21 12 20
Clots: other 14 24 15
Clots: oxygenator 12 12 12
Clots: bladder 13 6 12
Clots: bridge 9 9 9
Oxygenator failure 5 3 5
Air in the circuit 3 9 3
Hemorrhagic
Cannulation site bleeding 17 15 17
Surgical site bleeding 3 9 4
Hemolysis* 4 15 5
Disseminated intravascular coagulation (DIC) 5 0 4
Neurologic
Brain death clinically determined 1 0 0.4
Seizures: clinically determined 5 6 5
CNS infarction by US / CT 1.7 2.9 1.9
CNS hemorrhage by US / CT 3.8 0 3.3
Renal
Hemofiltration required 24 12 23
CAVHD required 4 3 4
Cardiovascular
Inotropes on ECLS 44 47 44
Hypertension requiring vasodilators 18 15 18
CPR required 6 0 5
Cardiac arrhythmia 4 3 4
Pulmonary
Pneumothorax requiring treatment 9 6 9
Pulmonary hemorrhage 7 3 6
Infectious
Culture proven infection 19 18 19
Metabolic
Hyperbilirubinemia (> 2 direct or > 15 total) 6 3 6
pH < 7.20 5 9 5
pH > 7.60 4 9 4
* p=0.007
Data are presented as a percentage (%) for categorical variables. Statistical significance was accepted at p < 0.05.
CAVHD, continuous arteriovenous hemodialysis; CNS, central nervous system; CPR, c-reactive protein; CT, computed tomo-
graphy; ECLS, extra corporeal life support; US, ultra sound; VV, veno-venous two site ECMO group; VVDL, veno venous double 
lumen ECMO group.
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– showed any significant superiority. 
The decision about which technique to 
use for infants depends mainly on best 
practice experiences of each individual 
ECMO centre and their routinely used 
technical equipment.
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